EE03484B1 - Farnesüülproteiintransferaasi inhibeerivad (5-imidasolüül)metüül-2-kinolinooni derivaadid ja nende kasutamine - Google Patents

Farnesüülproteiintransferaasi inhibeerivad (5-imidasolüül)metüül-2-kinolinooni derivaadid ja nende kasutamine

Info

Publication number: EE03484B1
Authority: EE; Estonia
Prior art keywords: imidazolyl; methyl; protein transferase; farnesyl protein; quinolinone derivatives
Prior art date: 1995-12-08

Application number

EE9800146A

Other languages

English (en)

Estonian (et)

Other versions

EE9800146A (et

Inventor

Gaston Venet Marc

Ren� Angibaud Patrick

Charles Sanz G�rard

Muller Philippe

Original Assignee

Janssen Pharmaceutica N.V.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-08

Filing date

1996-10-16

Publication date

2001-08-15

1996-10-16 Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.

1998-10-15 Publication of EE9800146A publication Critical patent/EE9800146A/xx

2001-08-15 Publication of EE03484B1 publication Critical patent/EE03484B1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Quinoline Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

EE9800146A 1995-12-08 1996-10-16 Farnesüülproteiintransferaasi inhibeerivad (5-imidasolüül)metüül-2-kinolinooni derivaadid ja nende kasutamine EE03484B1 (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP95203427		1995-12-08
PCT/EP1996/004515 WO1997021701A1 (en)	1995-12-08	1996-10-16	Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives

Publications (2)

Publication Number	Publication Date
EE9800146A EE9800146A (et)	1998-10-15
EE03484B1 true EE03484B1 (et)	2001-08-15

Family

ID=8220926

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EE9800146A EE03484B1 (et)	1995-12-08	1996-10-16	Farnesüülproteiintransferaasi inhibeerivad (5-imidasolüül)metüül-2-kinolinooni derivaadid ja nende kasutamine

Country Status (36)

Country	Link
US (3)	US6037350A (ko)
EP (2)	EP0865440B1 (ko)
JP (1)	JP3257559B2 (ko)
KR (1)	KR100272676B1 (ko)
CN (1)	CN1101392C (ko)
AP (1)	AP1108A (ko)
AR (1)	AR004992A1 (ko)
AT (2)	ATE215541T1 (ko)
AU (1)	AU711142B2 (ko)
BG (1)	BG62615B1 (ko)
BR (1)	BR9610745A (ko)
CA (1)	CA2231105C (ko)
CY (1)	CY2289B1 (ko)
CZ (1)	CZ293296B6 (ko)
DE (2)	DE69635966T2 (ko)
DK (2)	DK0865440T3 (ko)
EA (1)	EA000710B1 (ko)
EE (1)	EE03484B1 (ko)
ES (2)	ES2260156T3 (ko)
HK (2)	HK1012188A1 (ko)
HR (1)	HRP960576B1 (ko)
HU (1)	HU221227B1 (ko)
IL (1)	IL123568A (ko)
MX (1)	MX9802068A (ko)
MY (1)	MY114444A (ko)
NO (1)	NO314036B1 (ko)
NZ (1)	NZ320244A (ko)
PL (1)	PL184171B1 (ko)
PT (2)	PT865440E (ko)
SI (2)	SI1162201T1 (ko)
SK (1)	SK283335B6 (ko)
TR (1)	TR199800825T2 (ko)
TW (1)	TW494101B (ko)
UA (1)	UA57717C2 (ko)
WO (1)	WO1997021701A1 (ko)
ZA (1)	ZA9610254B (ko)

Families Citing this family (229)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2260156T3 (es) *	1995-12-08	2006-11-01	Janssen Pharmaceutica N.V.	Derivados de (imidazol-5-il)metil-2-quinolinona como inhibidores de la proteina farnesil-transferasa.
RU2209066C2 (ru)	1997-06-02	2003-07-27	Янссен Фармацевтика Н.В.	Производные (имидазол-5-ил)метил-2-хинолинона в качестве ингибиторов пролиферации клеток гладкой мышцы
US20030114503A1 (en) *	1997-06-16	2003-06-19	Pfizer Inc.	Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer
ATE262520T1 (de) *	1998-06-16	2004-04-15	Sod Conseils Rech Applic	Imidazol-derivate
US6420555B1 (en)	1998-06-16	2002-07-16	Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S.	Imidazolyl derivatives
BR9911869A (pt) *	1998-07-06	2001-03-27	Janssen Pharmaceutica Nv	Inibidores da transferase da proteìna farnesil para o tratamento das artropatias
JP4530537B2 (ja) *	1998-07-06	2010-08-25	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	インビボ放射線増感特性をもつファルネシルタンパク質トランスフェラーゼ阻害剤
FR2780892B1 (fr) *	1998-07-08	2001-08-17	Sod Conseils Rech Applic	Utilisation d'inhibiteurs de prenyltransferases pour preparer un medicament destine a traiter les pathologies qui resultent de la fixation membranaire de la proteine g heterotrimerique
CA2341739C (en) *	1998-08-27	2005-07-12	Pfizer Products Inc.	Quinolin-2-one derivatives useful as anticancer agents
ID27562A (id) *	1998-08-27	2001-04-12	Pfizer Prod Inc	Turunan-turunan kinolin-2-ona tersubstitusi alkunil yang berguna sebagai zat anti kanker
AU2477400A (en)	1998-12-08	2000-06-26	Merck & Co., Inc.	Inhibitors of prenyl-protein transferase
AU2478500A (en)	1998-12-08	2000-06-26	Merck & Co., Inc.	Inhibitors of prenyl-protein transferase
ATE240327T1 (de) *	1998-12-23	2003-05-15	Janssen Pharmaceutica Nv	1,2-annelierte chinolinderivate
UA71945C2 (en)	1999-01-27	2005-01-17	Pfizer Prod Inc	Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja)	1999-01-27	2002-04-02	ファイザー・プロダクツ・インク	抗がん剤として有用なヘテロ芳香族二環式誘導体
PL349839A1 (en)	1999-02-11	2002-09-23	Pfizer Prod Inc	Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents
US6143766A (en) *	1999-04-16	2000-11-07	Warner-Lambert Company	Benzopyranone and quinolone inhibitors of ras farnesyl transferase
EP1420015A1 (en) *	1999-06-11	2004-05-19	Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S.	Imidazolyl derivatives
FR2796943A1 (fr) *	1999-07-30	2001-02-02	Aventis Pharma Sa	Derives de benzoxazinnes, leur procede de preparation et leur utilisation en therapeutique
PL204716B1 (pl) *	1999-11-09	2010-02-26	Sod Conseils Rech Applic	Produkt zawierający inhibitor transdukcji sygnałów heterotrimerycznego białka G w kombinacji z innym środkiem przeciwrakowym do stosowania terapeutycznego w leczeniu raka
ATE259365T1 (de) *	1999-11-30	2004-02-15	Pfizer Prod Inc	Chinolinderivate verwendbar zur hemmung der farnesyl-protein transferase
HN2000000266A (es) *	2000-01-21	2001-05-21	Pfizer Prod Inc	Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
JP5491681B2 (ja) *	2000-02-04	2014-05-14	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	乳ガンの治療のためのファルネシルタンパク質トランスフェラーゼ阻害剤
US6838467B2 (en)	2000-02-24	2005-01-04	Janssen Pharmaceutica N. V.	Dosing regimen
EP1261341A2 (en) *	2000-02-29	2002-12-04	Janssen Pharmaceutica N.V.	Farnesyl protein transferase inhibitor combinations with camptothecin compounds
EP1263437A2 (en) *	2000-02-29	2002-12-11	Janssen Pharmaceutica N.V.	Farnesyl protein transferase inhibitor combinations with vinca alkaloids
US20030125326A1 (en) *	2000-02-29	2003-07-03	Rybak Mary Ellen Margaret	Farnesyl protein transferase inhibitor combinations
AU2001246478A1 (en) *	2000-02-29	2001-09-12	Janssen Pharmaceutica N.V.	Farnesyl protein transferase inhibitor combinations with taxane compounds
AU2001239275A1 (en) *	2000-02-29	2001-09-12	Janssen Pharmaceutica N.V.	Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
JP2003525252A (ja) *	2000-02-29	2003-08-26	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Ｈｅｒ２抗体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
EP1261348A2 (en) *	2000-02-29	2002-12-04	Janssen Pharmaceutica N.V.	Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
AU2001244167A1 (en) *	2000-02-29	2001-09-12	Janssen Pharmaceutica N.V.	Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
US20030186925A1 (en) *	2000-02-29	2003-10-02	Palmer Peter Albert	Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
JP2003525246A (ja) *	2000-02-29	2003-08-26	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	白金化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
AU2001244166A1 (en) *	2000-02-29	2001-09-12	Janssen Pharmaceutica N.V.	Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
US6844357B2 (en) *	2000-05-01	2005-01-18	Pfizer Inc.	Substituted quinolin-2-one derivatives useful as antiproliferative agents
JO2361B1 (en) *	2000-06-22	2006-12-12	جانسين فارماسيوتيكا ان. في	Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
EP1322644A1 (en) *	2000-09-25	2003-07-02	Janssen Pharmaceutica N.V.	Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
AU2001293829A1 (en) *	2000-09-25	2002-04-02	Janssen Pharmaceutica N.V.	Farnesyl transferase inhibiting 6-((substituted phenyl)methyl)-quinoline and quinazoline derivatives
ES2313991T3 (es)	2000-09-25	2009-03-16	Janssen Pharmaceutica Nv	Derivados de 6-heterociclilmetil-quinolina y quinazolina que inhiben la farnesil transferasa.
AU2001293826A1 (en)	2000-09-25	2002-04-02	Janssen Pharmaceutica N.V.	Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
AU2002214056A1 (en)	2000-11-21	2002-06-03	Janssen Pharmaceutica N.V.	Farnesyl transferase inhibiting benzoheterocyclic derivatives
JP4231691B2 (ja) *	2000-11-28	2009-03-04	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	炎症性腸疾患の治療のためのファルネシルタンパク質トランスフェラーゼ阻害剤
EP1395577A1 (en)	2000-12-19	2004-03-10	Pfizer Products Inc.	Crystal forms of 6- (4-chloro-phenyl)-hydroxy-(-3-methyl-3h-imidaol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinolin-2-one, 2,3-dihydroxybutanedioate salts and method of production
EP1351954B1 (en) *	2000-12-27	2006-05-03	Janssen Pharmaceutica N.V.	Farnesyl transferase inhibiting 4-heterocyclyl-quinoline and quinazoline derivatives
WO2002051835A1 (en) *	2000-12-27	2002-07-04	Janssen Pharmaceutica N.V.	Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
WO2002056884A2 (en)	2001-01-22	2002-07-25	Schering Corporation	Treatment of malaria with farnesyl protein transferase inhibitors
US20040110769A1 (en) *	2001-02-15	2004-06-10	End David William	Farnesyl protein transferase inhibitor combinations with antiestrogen agents
EA006770B1 (ru) *	2001-03-12	2006-04-28	Янссен Фармацевтика Н.В.	Способ получения соединений имидазола
US20020151563A1 (en) *	2001-03-29	2002-10-17	Pfizer Inc.	Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
EP1408971A4 (en)	2001-06-21	2006-01-25	Ariad Pharma Inc	NEW QUINOLINES AND THEIR USES
US6706699B2 (en)	2001-06-21	2004-03-16	Ariad Pharmaceuticals, Inc.	Quinolines and uses thereof
US6740757B2 (en)	2001-08-29	2004-05-25	Pfizer Inc	Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
US20030134846A1 (en) *	2001-10-09	2003-07-17	Schering Corporation	Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
ATE425978T1 (de)	2001-12-19	2009-04-15	Janssen Pharmaceutica Nv	Durch c-verbundene imidazole substituierte 1,8- annellierten chinolon-derivate als farnesyl transferase inhibitoren
ES2287466T3 (es)	2002-03-22	2007-12-16	Janssen Pharmaceutica N.V.	Derivados de 2-quinolinona y quinazolina de bencilimidazolil sustituidas como inhibidores de la farnesil transferasa.
EP1497295B1 (en)	2002-04-15	2006-08-16	Janssen Pharmaceutica N.V.	Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
US7425618B2 (en)	2002-06-14	2008-09-16	Medimmune, Inc.	Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en)	2002-06-14	2006-11-07	Medimmune, Inc.	Stabilized liquid anti-RSV antibody formulations
US20030125268A1 (en) *	2002-08-28	2003-07-03	Rybak Mary Ellen Margaret	Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
WO2004022097A1 (en) *	2002-09-05	2004-03-18	Medimmune, Inc.	Methods of preventing or treating cell malignancies by administering cd2 antagonists
US7563810B2 (en) *	2002-11-06	2009-07-21	Celgene Corporation	Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) *	2002-11-06	2011-10-11	Celgene Corporation	Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
KR101224235B1 (ko)	2003-04-11	2013-01-25	메디뮨 엘엘씨	재조합 ｉｌ９ 항체 및 그의 용도
US20050003422A1 (en)	2003-07-01	2005-01-06	Mitch Reponi	Methods for assessing and treating cancer
WO2005009967A2 (en) *	2003-07-22	2005-02-03	Janssen Pharmaceutica, N.V.	Quinolinone derivatives as inhibitors of c-fms kinase
US20060228350A1 (en) *	2003-08-18	2006-10-12	Medimmune, Inc.	Framework-shuffling of antibodies
JP4934426B2 (ja)	2003-08-18	2012-05-16	メディミューン，エルエルシー	抗体のヒト化
CA2539760C (en)	2003-09-23	2011-01-25	Merck & Co., Inc.	Quinoline potassium channel inhibitors
JP2007538004A (ja) *	2004-03-18	2007-12-27	ザブライハムアンドウイメンズホスピタル，インコーポレイテッド	シヌクレイノパチーを治療する方法
WO2005089515A2 (en) *	2004-03-18	2005-09-29	The Brigham And Women's Hospital, Inc.	Methods for the treatment of synucleinopathies
US20070293539A1 (en) *	2004-03-18	2007-12-20	Lansbury Peter T	Methods for the treatment of synucleinopathies
WO2005089502A2 (en) *	2004-03-18	2005-09-29	The Brigham And Women's Hospital, Inc.	Methods for the treatment of synucleinopathies
US20050272068A1 (en) *	2004-03-18	2005-12-08	The Brigham And Women's Hospital, Inc.	UCH-L1 expression and cancer therapy
WO2005089496A2 (en) *	2004-03-18	2005-09-29	The Brigham And Women's Hospital, Inc.	Methods for the treatment of synucleinopathies
EP1758885B1 (en)	2004-05-03	2008-06-18	Janssen Pharmaceutica N.V.	Diastereoselective addition of lithiated n-methylimidazole on sulfinimines
ATE471316T1 (de) *	2004-05-03	2010-07-15	Janssen Pharmaceutica Nv	Diastereoselektives syntheseverfahren mit 6-brom- 4-(3-chlorphenyl)-2-methoxychinolin
ES2308486T3 (es) *	2004-05-03	2008-12-01	Janssen Pharmaceutica Nv	Proceso de sintesis diastereoselectiva para la preparacion de compuestos de imidazol.
JP2008504292A (ja)	2004-06-24	2008-02-14	ノバルティスヴァクシンズアンドダイアグノスティクス，インコーポレイテッド	免疫増強用の化合物
GB0420722D0 (en)	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
US20060121042A1 (en)	2004-10-27	2006-06-08	Medimmune, Inc.	Modulation of antibody specificity by tailoring the affinity to cognate antigens
ES2522830T3 (es) *	2004-11-05	2014-11-18	Janssen Pharmaceutica N.V.	Métodos de control de la eficacia de los inhibidores de la farnesiltransferasa
US20060194821A1 (en) *	2005-02-18	2006-08-31	The Brigham And Women's Hospital, Inc.	Compounds inhibiting the aggregation of superoxide dismutase-1
EP1869192B1 (en)	2005-03-18	2016-01-20	MedImmune, LLC	Framework-shuffling of antibodies
EP1888050B1 (en)	2005-05-17	2012-03-21	Merck Sharp & Dohme Ltd.	cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer
US20060281788A1 (en) *	2005-06-10	2006-12-14	Baumann Christian A	Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US20060281769A1 (en) *	2005-06-10	2006-12-14	Baumann Christian A	Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
US20060281755A1 (en) *	2005-06-10	2006-12-14	Baumann Christian A	Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20070004660A1 (en) *	2005-06-10	2007-01-04	Baumann Christian A	Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines
JP2008546805A (ja)	2005-06-23	2008-12-25	メディミューン，エルエルシー	最適な凝集および断片化プロフィールを有する抗体製剤
JP5225092B2 (ja) *	2005-10-14	2013-07-03	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	チピファルニブの新規ｉｖ調合物
WO2007075923A2 (en)	2005-12-23	2007-07-05	Link Medicine Corporation	Treatment of synucleinopathies
JO2660B1 (en)	2006-01-20	2012-06-17	نوفارتيس ايه جي	Pi-3 inhibitors and methods of use
GB0603041D0 (en)	2006-02-15	2006-03-29	Angeletti P Ist Richerche Bio	Therapeutic compounds
TWI417095B (zh)	2006-03-15	2013-12-01	Janssen Pharmaceuticals Inc	１，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200808739A (en)	2006-04-06	2008-02-16	Novartis Vaccines & Diagnostic	Quinazolines for PDK1 inhibition
MX2008013533A (es)	2006-04-20	2009-01-15	Janssen Pharmaceutica Nv	Compuestos heterociclicos como inhibidores de c-fms cinasa.
NZ572072A (en)	2006-04-20	2011-09-30	Janssen Pharmaceutica Nv	Inhibitors of c-fms kinase
US8697716B2 (en)	2006-04-20	2014-04-15	Janssen Pharmaceutica Nv	Method of inhibiting C-KIT kinase
TWI405771B (zh)	2006-08-28	2013-08-21	Kyowa Hakko Kirin Co Ltd	具拮抗性之人類ｌｉｇｈｔ專一性人類單株抗體
EP2946778A1 (en)	2006-09-22	2015-11-25	Merck Sharp & Dohme Corp.	Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en)	2006-11-01	2011-09-08	Barbara Brooke Jennings-Spring	Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CA2674436C (en)	2007-01-10	2012-07-17	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.	Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
CN101679266B (zh)	2007-03-01	2015-05-06	诺华股份有限公司	Pim激酶抑制剂及其应用方法
TW200900065A (en)	2007-03-07	2009-01-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en)	2007-03-07	2008-12-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US20110130544A1 (en)	2007-03-30	2011-06-02	Medimmune, Llc	Antibodies with decreased deamidation profiles
JO2959B1 (en)	2007-05-14	2016-03-15	جانسين فارماسوتيكا ان. في	Mono-hydrochloric salts for histone dacetylase inhibitor
US8293769B2 (en)	2007-05-21	2012-10-23	Novartis Ag	CSF-1R inhibitors, compositions, and methods of use
BRPI0811781A2 (pt) *	2007-05-23	2014-11-11	Allergan Inc	Compostos de ((fenil) imidazolil)metilquinolinila terapêuticos.
WO2009002495A1 (en)	2007-06-27	2008-12-31	Merck & Co., Inc.	4-carboxybenzylamino derivatives as histone deacetylase inhibitors
NZ584152A (en)	2007-09-14	2011-11-25	Ortho Mcneil Janssen Pharm	1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
ES2356032T3 (es)	2007-09-14	2011-04-04	Ortho-Mcneil-Janssen Pharmaceuticals, Inc.	4-fenil-3,4,5,6-tetrahidro-2h,1'h-[1,4']bipiridinil-2'-onas 1,3'-disustituidas.
JO3240B1 (ar)	2007-10-17	2018-03-08	Janssen Pharmaceutica Nv	c-fms مثبطات كيناز
US8633297B2 (en)	2007-10-31	2014-01-21	Medimmune, Llc	Protein scaffolds
AU2008350907A1 (en)	2007-12-11	2009-08-27	Viamet Pharmaceuticals, Inc.	Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
JP2011506560A (ja)	2007-12-20	2011-03-03	ノバルティスアーゲー	Ｐｉ３キナーゼ阻害剤として用いられるチアゾール誘導体
WO2009151683A2 (en) *	2008-03-12	2009-12-17	Link Medicine Corporation	Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
US7932036B1 (en)	2008-03-12	2011-04-26	Veridex, Llc	Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
JP5547194B2 (ja)	2008-09-02	2014-07-09	ジャンセンファーマシューティカルズ，インコーポレイテッド．	代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体
US20100331363A1 (en) *	2008-11-13	2010-12-30	Link Medicine Corporation	Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
AU2009313906A1 (en) *	2008-11-13	2010-05-20	Link Medicine Corporation	Treatment of proteinopathies using a farnesyl transferase inhibitor
US8343996B2 (en) *	2008-11-13	2013-01-01	Astrazeneca Ab	Azaquinolinone derivatives and uses thereof
US20110060005A1 (en) *	2008-11-13	2011-03-10	Link Medicine Corporation	Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
CN102232074B (zh)	2008-11-28	2014-12-03	奥梅-杨森制药有限公司	作为代谢性谷氨酸盐受体调节剂的吲哚和苯并噁嗪衍生物
EP2413932A4 (en)	2009-04-01	2012-09-19	Merck Sharp & Dohme	INHIBITORS OF AKT ACTIVITY
MY153913A (en)	2009-05-12	2015-04-15	Janssen Pharmaceuticals Inc	7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY161325A (en)	2009-05-12	2017-04-14	Janssen Pharmaceuticals Inc	1, 2, 4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
BRPI1010831A2 (pt)	2009-05-12	2016-04-05	Addex Pharmaceuticals Sa	derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
CN102480966B (zh)	2009-06-12	2015-09-16	达娜-法勃肿瘤研究所公司	融合的杂环化合物及其用途
US8293753B2 (en)	2009-07-02	2012-10-23	Novartis Ag	Substituted 2-carboxamide cycloamino ureas
JP5099731B1 (ja)	2009-10-14	2012-12-19	メルク・シャープ・アンド・ドーム・コーポレーション	ｐ５３活性を増大する置換ピペリジン及びその使用
EP2519517B1 (en)	2009-12-29	2015-03-25	Dana-Farber Cancer Institute, Inc.	Type ii raf kinase inhibitors
US8987275B2 (en)	2010-03-16	2015-03-24	Dana-Farber Cancer Institute, Inc.	Indazole compounds and their uses
US8999957B2 (en)	2010-06-24	2015-04-07	Merck Sharp & Dohme Corp.	Heterocyclic compounds as ERK inhibitors
AU2011282614B2 (en)	2010-07-28	2015-11-26	Janssen Pharmaceutica Nv	Methods of determining Acute Myeloid Leukemia response to treatment with farnesyltransferase inhibitors
CN103068980B (zh)	2010-08-02	2017-04-05	瑟纳治疗公司	使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
AR082418A1 (es)	2010-08-02	2012-12-05	Novartis Ag	Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
WO2012024170A2 (en)	2010-08-17	2012-02-23	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2608669B1 (en)	2010-08-23	2016-06-22	Merck Sharp & Dohme Corp.	NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en)	2010-09-01	2012-03-08	Schering Corporation	Indazole derivatives useful as erk inhibitors
EP2615916B1 (en)	2010-09-16	2017-01-04	Merck Sharp & Dohme Corp.	Fused pyrazole derivatives as novel erk inhibitors
DK2632472T3 (en)	2010-10-29	2018-03-19	Sirna Therapeutics Inc	RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
WO2012062751A1 (en)	2010-11-08	2012-05-18	Janssen Pharmaceuticals, Inc.	1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
ES2552455T3 (es)	2010-11-08	2015-11-30	Janssen Pharmaceuticals, Inc.	Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
ES2552879T3 (es)	2010-11-08	2015-12-02	Janssen Pharmaceuticals, Inc.	Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
WO2012087772A1 (en)	2010-12-21	2012-06-28	Schering Corporation	Indazole derivatives useful as erk inhibitors
EP2668210B1 (en)	2011-01-26	2020-06-17	Celldex Therapeutics, Inc.	Anti-kit antibodies and uses thereof
KR101928116B1 (ko)	2011-01-31	2018-12-11	노파르티스 아게	신규 헤테로시클릭 유도체
US20140045847A1 (en)	2011-04-21	2014-02-13	Piramal Enterprises Limited	Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
WO2013063214A1 (en)	2011-10-27	2013-05-02	Merck Sharp & Dohme Corp.	Novel compounds that are erk inhibitors
JP6059731B2 (ja)	2011-10-28	2017-01-11	ノバルティスアーゲー	新規プリン誘導体および疾患の処置におけるその使用
JP6106685B2 (ja)	2011-11-17	2017-04-05	ダナ−ファーバーキャンサーインスティテュート，インコーポレイテッド	Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
WO2013165816A2 (en)	2012-05-02	2013-11-07	Merck Sharp & Dohme Corp.	SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
KR20150009540A (ko)	2012-05-16	2015-01-26	노파르티스 아게	Pi-3 키나제 억제제에 대한 투여 요법
DK2877493T3 (en)	2012-07-25	2018-06-14	Celldex Therapeutics Inc	ANTI-KIT ANTIBODIES AND APPLICATIONS THEREOF
JOP20180012A1 (ar)	2012-08-07	2019-01-30	Janssen Pharmaceutica Nv	عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
AU2013299922B2 (en)	2012-08-07	2018-06-21	Janssen Pharmaceutica Nv	Process for the preparation of heterocyclic ester derivatives
WO2014052563A2 (en)	2012-09-28	2014-04-03	Merck Sharp & Dohme Corp.	Novel compounds that are erk inhibitors
JP2015533832A (ja)	2012-10-09	2015-11-26	アイジェニカバイオセラピューティクスインコーポレイテッド	抗Ｃ１６ｏｒｆ５４抗体およびその使用方法
ES2632269T3 (es)	2012-10-16	2017-09-12	Janssen Pharmaceutica Nv	Moduladores de quinolinailo enlazados a metileno de ROR-gamma-t
CN104884448A (zh)	2012-10-16	2015-09-02	詹森药业有限公司	Rorγt的杂芳基连接的喹啉基调节剂
JP6251277B2 (ja)	2012-10-16	2017-12-20	ヤンセンファーマシューティカエヌ．ベー．	ＲＯＲ−ガンマ−ｔのフェニル結合キノリニルモジュレーター
EP2909194A1 (en)	2012-10-18	2015-08-26	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2014063054A1 (en)	2012-10-19	2014-04-24	Dana-Farber Cancer Institute, Inc.	Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
WO2014063061A1 (en)	2012-10-19	2014-04-24	Dana-Farber Cancer Institute, Inc.	Hydrophobically tagged small molecules as inducers of protein degradation
RU2660349C2 (ru)	2012-11-28	2018-07-05	Мерк Шарп И Доум Корп.	Композиции и способы для лечения злокачественной опухоли
EP2935263B1 (en)	2012-12-20	2018-12-05	Merck Sharp & Dohme Corp.	Substituted imidazopyridines as hdm2 inhibitors
EP2951180B1 (en)	2013-01-30	2018-05-02	Merck Sharp & Dohme Corp.	2,6,7,8 substituted purines as hdm2 inhibitors
JO3368B1 (ar)	2013-06-04	2019-03-13	Janssen Pharmaceutica Nv	مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
NZ714765A (en)	2013-06-06	2021-12-24	Pf Medicament	Anti-c10orf54 antibodies and uses thereof
US9475874B2 (en)	2013-08-26	2016-10-25	MabVax Therapeutics, Inc.	Nucleic acids encoding human antibodies to sialyl-lewisa
US20160194368A1 (en)	2013-09-03	2016-07-07	Moderna Therapeutics, Inc.	Circular polynucleotides
JO3367B1 (ar)	2013-09-06	2019-03-13	Janssen Pharmaceutica Nv	مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
CN105873439A (zh)	2013-10-15	2016-08-17	詹森药业有限公司	RORγt的烷基连接的喹啉基调节剂
US9284308B2 (en)	2013-10-15	2016-03-15	Janssen Pharmaceutica Nv	Methylene linked quinolinyl modulators of RORγt
US9403816B2 (en)	2013-10-15	2016-08-02	Janssen Pharmaceutica Nv	Phenyl linked quinolinyl modulators of RORγt
US9328095B2 (en)	2013-10-15	2016-05-03	Janssen Pharmaceutica Nv	Heteroaryl linked quinolinyl modulators of RORgammat
WO2015057626A1 (en)	2013-10-15	2015-04-23	Janssen Pharmaceutica Nv	QUINOLINYL MODULATORS OF RORyT
US9221804B2 (en)	2013-10-15	2015-12-29	Janssen Pharmaceutica Nv	Secondary alcohol quinolinyl modulators of RORγt
US10555941B2 (en)	2013-10-15	2020-02-11	Janssen Pharmaceutica Nv	Alkyl linked quinolinyl modulators of RORγt
AU2014337122B2 (en)	2013-10-18	2019-01-03	Dana-Farber Cancer Institute, Inc.	Heteroaromatic compounds useful for the treatment of proliferative diseases
EP3057956B1 (en)	2013-10-18	2021-05-05	Dana-Farber Cancer Institute, Inc.	Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
JP2016539149A (ja)	2013-12-06	2016-12-15	ノバルティスアーゲー	アルファ−アイソフォーム選択的ホスファチジルイノシトール３−キナーゼ阻害剤の投薬レジメン
EP3431106B1 (en)	2014-01-21	2020-12-30	Janssen Pharmaceutica NV	Combinations comprising positive allosteric modulators of metabotropic glutamatergic receptor subtype 2 and their use
KR20200126026A (ko)	2014-01-21	2020-11-05	얀센 파마슈티카 엔.브이.	대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
WO2015164604A1 (en)	2014-04-23	2015-10-29	Dana-Farber Cancer Institute, Inc.	Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (en)	2014-04-23	2015-10-29	Dana-Farber Cancer Institute, Inc.	Janus kinase inhibitors and uses thereof
US10076512B2 (en)	2014-05-01	2018-09-18	Eiger Biopharmaceuticals, Inc.	Treatment of hepatitis delta virus infection
US11311519B2 (en)	2014-05-01	2022-04-26	Eiger Biopharmaceuticals, Inc.	Treatment of hepatitis delta virus infection
KR102226248B1 (ko)	2014-06-04	2021-03-12	바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드	강글리오사이드 ｇｄ２에 대한 사람 단클론 항체
JO3589B1 (ar)	2014-08-06	2020-07-05	Novartis Ag	مثبطات كيناز البروتين c وطرق استخداماتها
AU2015360282B2 (en)	2014-12-11	2021-04-01	Pierre Fabre Medicament	Anti-C10orf54 antibodies and uses thereof
JP6854762B2 (ja)	2014-12-23	2021-04-07	ダナ−ファーバーキャンサーインスティテュート，インコーポレイテッド	サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
EP4137157A1 (en)	2015-03-03	2023-02-22	Kymab Limited	Antibodies, uses and methods
CN107427521B (zh)	2015-03-27	2021-08-03	达纳-法伯癌症研究所股份有限公司	细胞周期蛋白依赖性激酶的抑制剂
EP3285768B1 (en)	2015-04-21	2020-12-30	Eiger Biopharmaceuticals, Inc.	Pharmaceutical compositions comprising lonafarnib and ritonavir
WO2016201370A1 (en)	2015-06-12	2016-12-15	Dana-Farber Cancer Institute, Inc.	Combination therapy of transcription inhibitors and kinase inhibitors
RS62709B1 (sr) *	2015-08-17	2022-01-31	Kura Oncology Inc	Postupci za lečenje pacijenata obolelih od kancera pomoću inhibitora farneziltransferaze
WO2017034877A1 (en) *	2015-08-27	2017-03-02	Janssen Pharmaceutica Nv	Chemically modified quinoline and quinolone derivatives useful as cb-1 inverse agonists
CA2996978A1 (en)	2015-09-09	2017-03-16	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinases
US20180280370A1 (en)	2015-11-02	2018-10-04	Novartis Ag	Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
EP3383908A1 (en)	2015-12-02	2018-10-10	Stsciences, Inc.	Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
MX2018006613A (es)	2015-12-02	2019-01-30	Stcube & Co Inc	Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
JOP20190055A1 (ar)	2016-09-26	2019-03-24	Merck Sharp & Dohme	أجسام مضادة ضد cd27
WO2018060833A1 (en)	2016-09-27	2018-04-05	Novartis Ag	Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
WO2018071283A1 (en)	2016-10-12	2018-04-19	Merck Sharp & Dohme Corp.	Kdm5 inhibitors
RS61745B1 (sr)	2016-11-03	2021-05-31	Kura Oncology Inc	Inhibitori farneziltransferaze za upotrebu u tretiranju kancera
EP3534947A1 (en)	2016-11-03	2019-09-11	Kymab Limited	Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018103027A1 (zh) *	2016-12-08	2018-06-14	杭州领业医药科技有限公司	替吡法尼的晶型及其制备方法及药物组合物
MX2019012233A (es)	2017-04-13	2020-01-14	Aduro Biotech Holdings Europe Bv	Anticuerpos anti-sirpa.
JP2020522512A (ja)	2017-05-31	2020-07-30	ストキューブアンドシーオー．，インコーポレイテッド	Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子を用いて癌を治療する方法
EP3630835A1 (en)	2017-05-31	2020-04-08	STCube & Co., Inc.	Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
JP2020522562A (ja)	2017-06-06	2020-07-30	ストキューブアンドシーオー．，インコーポレイテッド	Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法
JP7256796B2 (ja)	2017-10-13	2023-04-12	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｔｈｏｍｓｅｎ－ｎｏｕｖｅｌｌｅ（ｔｎ）抗原に対するヒト抗体
WO2019094311A1 (en)	2017-11-08	2019-05-16	Merck Sharp & Dohme Corp.	Prmt5 inhibitors
EP3706747A4 (en)	2017-11-08	2021-08-04	Merck Sharp & Dohme Corp.	PRMT5 INHIBITORS
WO2019113269A1 (en)	2017-12-08	2019-06-13	Kura Oncology, Inc.	Methods of treating cancer patients with farnesyltransferase inhibitors
WO2019148412A1 (en)	2018-02-01	2019-08-08	Merck Sharp & Dohme Corp.	Anti-pd-1/lag3 bispecific antibodies
EA202092787A1 (ru)	2018-05-18	2021-02-09	Кура Онколоджи, Инк.	Синтез типифарниба
EP3824287A1 (en)	2018-07-20	2021-05-26	Pierre Fabre Médicament	Receptor for vista
EP3833668A4 (en)	2018-08-07	2022-05-11	Merck Sharp & Dohme Corp.	PRMT5 INHIBITORS
US11981701B2 (en)	2018-08-07	2024-05-14	Merck Sharp & Dohme Llc	PRMT5 inhibitors
WO2020190604A1 (en)	2019-03-15	2020-09-24	Kura Oncology, Inc.	Methods of treating cancer patients with farnesyltransferase inhibitors
KR20240110978A (ko)	2021-11-30	2024-07-16	쿠라 온콜로지, 인크.	파네실 전이효소 억제 활성을 갖는 대환식 화합물
WO2023141082A1 (en) *	2022-01-20	2023-07-27	Teva Czech Industries S.R.O.	Solid state forms of tipifarnib and process for preparation thereof
WO2024180169A1 (en)	2023-03-02	2024-09-06	Carcimun Biotech Gmbh	Means and methods for diagnosing cancer and/or an acute inflammatory disease
CN117229206A (zh) *	2023-09-18	2023-12-15	延安大学	一种碱催化合成多取代2-喹啉酮类化合物的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2101115A (en) *	1980-10-23	1983-01-12	Pfizer Ltd	Thromboxane synthetase inhibitors
CA2002864C (en) *	1988-11-29	1999-11-16	Eddy J. E. Freyne	(1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
ES2260156T3 (es) *	1995-12-08	2006-11-01	Janssen Pharmaceutica N.V.	Derivados de (imidazol-5-il)metil-2-quinolinona como inhibidores de la proteina farnesil-transferasa.

1996
- 1996-10-16 ES ES01202750T patent/ES2260156T3/es not_active Expired - Lifetime
- 1996-10-16 TR TR1998/00825T patent/TR199800825T2/xx unknown
- 1996-10-16 AT AT96934727T patent/ATE215541T1/de active
- 1996-10-16 ES ES96934727T patent/ES2175137T3/es not_active Expired - Lifetime
- 1996-10-16 WO PCT/EP1996/004515 patent/WO1997021701A1/en active IP Right Grant
- 1996-10-16 PT PT96934727T patent/PT865440E/pt unknown
- 1996-10-16 CN CN96198750A patent/CN1101392C/zh not_active Expired - Lifetime
- 1996-10-16 CA CA002231105A patent/CA2231105C/en not_active Expired - Lifetime
- 1996-10-16 BR BR9610745A patent/BR9610745A/pt not_active IP Right Cessation
- 1996-10-16 SI SI9630736T patent/SI1162201T1/sl unknown
- 1996-10-16 PL PL96325962A patent/PL184171B1/pl unknown
- 1996-10-16 DE DE69635966T patent/DE69635966T2/de not_active Expired - Lifetime
- 1996-10-16 DK DK96934727T patent/DK0865440T3/da active
- 1996-10-16 NZ NZ320244A patent/NZ320244A/xx not_active IP Right Cessation
- 1996-10-16 HU HU9900185A patent/HU221227B1/hu unknown
- 1996-10-16 PT PT01202750T patent/PT1162201E/pt unknown
- 1996-10-16 CZ CZ19981573A patent/CZ293296B6/cs not_active IP Right Cessation
- 1996-10-16 IL IL12356896A patent/IL123568A/en not_active IP Right Cessation
- 1996-10-16 JP JP52163897A patent/JP3257559B2/ja not_active Expired - Lifetime
- 1996-10-16 KR KR1019980702363A patent/KR100272676B1/ko not_active IP Right Cessation
- 1996-10-16 US US09/084,717 patent/US6037350A/en not_active Expired - Lifetime
- 1996-10-16 DK DK01202750T patent/DK1162201T3/da active
- 1996-10-16 SI SI9630477T patent/SI0865440T1/xx unknown
- 1996-10-16 SK SK704-98A patent/SK283335B6/sk not_active IP Right Cessation
- 1996-10-16 AP APAP/P/1998/001257A patent/AP1108A/en active
- 1996-10-16 EP EP96934727A patent/EP0865440B1/en not_active Expired - Lifetime
- 1996-10-16 UA UA98052686A patent/UA57717C2/uk unknown
- 1996-10-16 AT AT01202750T patent/ATE321757T1/de active
- 1996-10-16 EA EA199800443A patent/EA000710B1/ru not_active IP Right Cessation
- 1996-10-16 EE EE9800146A patent/EE03484B1/xx unknown
- 1996-10-16 EP EP01202750A patent/EP1162201B1/en not_active Expired - Lifetime
- 1996-10-16 DE DE69620445T patent/DE69620445T2/de not_active Expired - Lifetime
- 1996-10-16 AU AU72948/96A patent/AU711142B2/en not_active Expired
- 1996-11-30 TW TW085114832A patent/TW494101B/zh not_active IP Right Cessation
- 1996-12-05 HR HR960576A patent/HRP960576B1/xx not_active IP Right Cessation
- 1996-12-05 ZA ZA9610254A patent/ZA9610254B/xx unknown
- 1996-12-06 MY MYPI96005129A patent/MY114444A/en unknown
- 1996-12-06 AR ARP960105548A patent/AR004992A1/es active IP Right Grant
1998
- 1998-03-04 NO NO19980927A patent/NO314036B1/no not_active IP Right Cessation
- 1998-03-16 MX MX9802068A patent/MX9802068A/es unknown
- 1998-05-18 BG BG102458A patent/BG62615B1/xx unknown
- 1998-12-15 HK HK98113364A patent/HK1012188A1/xx not_active IP Right Cessation
1999
- 1999-07-29 US US09/363,353 patent/US6169096B1/en not_active Expired - Lifetime
2000
- 2000-10-12 US US09/689,211 patent/US6420387B1/en not_active Expired - Lifetime
2002
- 2002-04-17 HK HK02102891.4A patent/HK1042482B/zh not_active IP Right Cessation
- 2002-07-30 CY CY0200047A patent/CY2289B1/xx unknown

Also Published As

Publication number	Publication date
AU711142B2 (en)	1999-10-07
AP1108A (en)	2002-10-02
KR100272676B1 (ko)	2000-11-15
IL123568A (en)	2001-08-08
HK1012188A1 (en)	1999-07-30
CA2231105C (en)	2005-09-13
ES2260156T3 (es)	2006-11-01
PT1162201E (pt)	2006-08-31
NO314036B1 (no)	2003-01-20
SK283335B6 (sk)	2003-06-03
HRP960576B1 (en)	2002-04-30
AU7294896A (en)	1997-07-03
BR9610745A (pt)	1999-07-13
DE69620445D1 (de)	2002-05-08
SK70498A3 (en)	1998-10-07
DE69635966D1 (de)	2006-05-18
CZ157398A3 (cs)	1998-10-14
DK1162201T3 (da)	2006-07-17
CY2289B1 (en)	2003-07-04
AP9801257A0 (en)	1998-06-30
NZ320244A (en)	1999-06-29
ATE215541T1 (de)	2002-04-15
KR19990063891A (ko)	1999-07-26
EA199800443A1 (ru)	1998-10-29
SI1162201T1 (sl)	2006-08-31
ZA9610254B (en)	1998-06-05
HK1042482B (zh)	2006-06-09
DK0865440T3 (da)	2002-07-22
MY114444A (en)	2002-10-31
CN1101392C (zh)	2003-02-12
US6037350A (en)	2000-03-14
CZ293296B6 (cs)	2004-03-17
AR004992A1 (es)	1999-04-07
EP1162201B1 (en)	2006-03-29
WO1997021701A1 (en)	1997-06-19
BG102458A (en)	1999-06-30
JP3257559B2 (ja)	2002-02-18
HRP960576A2 (en)	1998-02-28
PL184171B1 (pl)	2002-09-30
EE9800146A (et)	1998-10-15
PL325962A1 (en)	1998-08-17
TW494101B (en)	2002-07-11
NO980927L (no)	1998-06-08
ATE321757T1 (de)	2006-04-15
CA2231105A1 (en)	1997-06-19
JPH10511405A (ja)	1998-11-04
EA000710B1 (ru)	2000-02-28
US6420387B1 (en)	2002-07-16
IL123568A0 (en)	1998-10-30
DE69620445T2 (de)	2002-12-12
EP0865440B1 (en)	2002-04-03
DE69635966T2 (de)	2006-11-30
US6169096B1 (en)	2001-01-02
BG62615B1 (en)	2000-03-31
UA57717C2 (uk)	2003-07-15
MX9802068A (es)	1998-08-30
HUP9900185A3 (en)	1999-11-29
ES2175137T3 (es)	2002-11-16
NO980927D0 (no)	1998-03-04
EP1162201A3 (en)	2003-11-26
HUP9900185A2 (hu)	1999-04-28
HU221227B1 (en)	2002-08-28
TR199800825T2 (xx)	1998-08-21
HK1042482A1 (en)	2002-08-16
EP0865440A1 (en)	1998-09-23
EP1162201A9 (en)	2002-04-03
PT865440E (pt)	2002-09-30
SI0865440T1 (en)	2002-08-31
EP1162201A2 (en)	2001-12-12
CN1203598A (zh)	1998-12-30

Publication	Publication Date	Title
EE03484B1 (et)	2001-08-15	Farnesüülproteiintransferaasi inhibeerivad (5-imidasolüül)metüül-2-kinolinooni derivaadid ja nende kasutamine
IS4568A (is)	1997-09-24	Farnesýl-prótein transferasa latar
NO985405D0 (no)	1998-11-20	Inhibitorer av proteinfarnesyltransferase
FI952010A0 (fi)	1995-04-27	Farnesyyliproteiinitransferaasin estäjät
EE04309B1 (et)	2004-06-15	Farnesüül-proteiini transferaasi inhibiitorid
FI951554A (fi)	1995-10-01	Imidatsolipitoisia farnesyyliproteiinitransferaasi-inhibiittoreita
FI941519A0 (fi)	1994-03-31	Farnesyyliproteiinitransferaasin heterosyklisiä inhibiittoreita
BR9709974A (pt)	1999-08-10	Derivados de 2-(2-oxo-etidileno)-imidazolidin-4-ona e seu uso como inibidores da transferase da proteina de farnesila
NO973607D0 (no)	1997-08-05	Nye farnesyltransferaseinhibitorer, deres fremstilling og preparater inneholdende inhibitorene
BR9611724A (pt)	1999-06-01	Inibidor de quinase c de proteína
NO973222D0 (no)	1997-07-10	Nye farnesyl-transferase-inhibitorer, deres fremstilling samt farmasöytiske preparater inneholdende inhibitorene
NO973980D0 (no)	1997-08-29	Imiadazolderivater og medisinsk preparat
DE69613074D1 (de)	2001-07-05	Pasteureinrichtung
FI953170A0 (fi)	1995-06-27	Oligunokleotidit isoprenyyliproteiinitransferaasin ilmentämisen inhibiboimiseksi
BR9609723A (pt)	1999-03-16	Derivados da tricetona
AU4329397A (en)	1998-03-26	Semipeptoid farnesyl protein transferase inhibitors and analogs thereof
IT1279909B1 (it)	1997-12-18	Spaccalegna perfezionato

Legal Events

Date	Code	Title	Description
2003-02-17	KB4A	Valid patent at the end of a year	Effective date: 20021231
2004-02-16	KB4A	Valid patent at the end of a year	Effective date: 20031231
2005-02-15	KB4A	Valid patent at the end of a year	Effective date: 20041231
2006-02-15	KB4A	Valid patent at the end of a year	Effective date: 20051231
2007-02-15	KB4A	Valid patent at the end of a year	Effective date: 20061231
2008-02-15	KB4A	Valid patent at the end of a year	Effective date: 20071231
2009-02-16	KB4A	Valid patent at the end of a year	Effective date: 20081231
2010-02-15	KB4A	Valid patent at the end of a year	Effective date: 20091231
2011-02-15	KB4A	Valid patent at the end of a year	Effective date: 20101231